Insmed Inc. Files Definitive Proxy Statement

Ticker: INSM · Form: DEF 14A · Filed: 2024-04-01T00:00:00.000Z

Sentiment: neutral

Topics: Proxy Statement, DEF 14A, Insmed Inc., ARIKAYCE, Brensocatib

TL;DR

<b>Insmed Inc. filed its Definitive Proxy Statement, highlighting the launch of ARIKAYCE® and upcoming Phase 3 trial data for brensocatib.</b>

AI Summary

INSMED Inc (INSM) filed a Proxy Statement (DEF 14A) with the SEC on April 1, 2024. Insmed Inc. filed a Definitive Proxy Statement (DEF 14A) on April 1, 2024. The filing covers the period ending May 13, 2024. The company's principal executive offices are located at 700 US Highway 202/206, Bridgewater, NJ 08807. Insmed has successfully launched ARIKAYCE® for refractory MAC lung disease in the U.S., Europe, and Japan. The company is awaiting topline data from the Phase 3 ASPEN trial of brensocatib for bronchiectasis, expected in Q2 2024.

Why It Matters

For investors and stakeholders tracking INSMED Inc, this filing contains several important signals. This filing provides shareholders with crucial information regarding company governance, executive compensation, and strategic initiatives ahead of shareholder votes. The upcoming data from the brensocatib trial is a key catalyst that could significantly impact the company's future revenue streams and market position.

Risk Assessment

Risk Level: medium — INSMED Inc shows moderate risk based on this filing. The company is awaiting critical Phase 3 trial data for brensocatib, a key drug candidate, and its success is not guaranteed, posing a significant risk to future growth projections.

Analyst Insight

Monitor the upcoming topline data from the Phase 3 ASPEN trial for brensocatib, as positive results could be a significant catalyst for the stock.

Key Numbers

Key Players & Entities

FAQ

When did INSMED Inc file this DEF 14A?

INSMED Inc filed this Proxy Statement (DEF 14A) with the SEC on April 1, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by INSMED Inc (INSM).

Where can I read the original DEF 14A filing from INSMED Inc?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by INSMED Inc.

What are the key takeaways from INSMED Inc's DEF 14A?

INSMED Inc filed this DEF 14A on April 1, 2024. Key takeaways: Insmed Inc. filed a Definitive Proxy Statement (DEF 14A) on April 1, 2024.. The filing covers the period ending May 13, 2024.. The company's principal executive offices are located at 700 US Highway 202/206, Bridgewater, NJ 08807..

Is INSMED Inc a risky investment based on this filing?

Based on this DEF 14A, INSMED Inc presents a moderate-risk profile. The company is awaiting critical Phase 3 trial data for brensocatib, a key drug candidate, and its success is not guaranteed, posing a significant risk to future growth projections.

What should investors do after reading INSMED Inc's DEF 14A?

Monitor the upcoming topline data from the Phase 3 ASPEN trial for brensocatib, as positive results could be a significant catalyst for the stock. The overall sentiment from this filing is neutral.

Risk Factors

Key Dates

Glossary

DEF 14A
Definitive Proxy Statement filed with the SEC. (Provides shareholders with information on company matters, including director elections and executive compensation.)

Filing Stats: 4,376 words · 18 min read · ~15 pages · Grade level 12.9 · Accepted 2024-04-01 16:19:52

Key Financial Figures

Filing Documents

Security Ownership of Certain Beneficial Owners, Directors, and Management

Security Ownership of Certain Beneficial Owners, Directors, and Management 33 Proposal No. 2 Advisory Vote on the 2023 Compensation of our Named Executive Officers 36 Compensation Discussion and Analysis 41 Compensation Committee Report 62 Compensation Committee Interlocks and Insider Participation 73 Dodd-Frank Mandated Pay Ratio Disclosure 73 Dodd-Frank Mandated Pay Versus Performance Disclosure 74 Director Compensation 80 Proposal No. 3 Ratification of the Appointment of Independent Registered Public Accounting Firm 82 Proposal No. 4 Approval of Amendment No. 1 to the Insmed Incorporated Amended and Restated 2019 Incentive Plan 83 Proposals for 2025 Annual Meeting 95 Annual Report on Form 10-K 96 Separate Copies for Beneficial Holders 96 General Information About the Annual Meeting and Voting 97 Appendix A: Amendment No. 1 to the Insmed Incorporated Amended and Restated 2019 Incentive Plan A-1 In this Proxy Statement, we use the words "Insmed Incorporated" to refer to Insmed Incorporated, a Virginia corporation, and we use the words "Company," "Insmed," "we," "us," and "our" to refer to Insmed Incorporated and its consolidated subsidiaries. Insmed and ARIKAYCE are trademarks of Insmed Incorporated. This Proxy Statement also contains trademarks of third parties. Each trademark of another company appearing in this Proxy Statement is the property of its owner. INSMED PROXY STATEMENT 5 TABLE OF CONTENTS Proposal No. 1 ELECTION OF CLASS III DIRECTORS Our Bylaws currently provide that the number of directors constituting our Board will be designated by a resolution of the Board, provided that in no event will the size of the Board exceed 12 directors, consistent with the limitation in our Articles of Incorporation. Our Board has adopted resolutions providing for up to 10 directors. The directors are divided into three classes—Class I, Class II, and Class III. Each class of directors serves for three years on a stagger

: Gender Identity

Part I: Gender Identity Directors 3 6 0 0

: Demographic Background

Part II: Demographic Background African American or Black 0 0 0 0 Alaskan Native or Native American 0 0 0 0 Asian 0 1 0 0 Hispanic or Latinx 1 0 0 0 Native Hawaiian or Pacific Islander 0 0 0 0 White 2 5 0 0 Two or More Races or Ethnicities 0 0 0 0 LGBTQ+ 0 0 0 0 Did Not Disclose Demographic Background 0 0 0 0 16 INSMED PROXY STATEMENT TABLE OF CONTENTS CORPORATE GOVERNANCE Corporate Governance Matters Corporate Governance Materials and Practices Our written corporate governance materials, including our Bylaws, Corporate Governance Guidelines, Code of Business Conduct and Ethics, Audit Committee Charter, Compensation Committee Charter, Nominations and Governance Committee Charter, Science and Technology Committee Charter, and Director Resignation Policy are posted on our website at www.insmed.com under the heading "Investors—Corporate Governance." None of the information on or that can be accessed through our website is incorporated by reference in this Proxy Statement. Our corporate governance practices include the following: Director Independence and Leadership Structure 8 of our 9 directors are independent All Board committee members are independent Board has appointed a lead independent director with robust and defined responsibilities, which our Corporate Governance Guidelines require if the positions of Chair and CEO are combined Executive sessions are regularly held at the end of Board and committee meetings Compensation Committee utilizes independent compensation consultant Board Oversight Board and Compensation Committee oversee succession planning for executive officers, including the CEO Board oversees our environmental, social and governance ("ESG") sustainability efforts and initiatives and has designated responsibilities for various components of ESG to our Nominations and Governance Committee and the Compensation Committee Compensation Committee oversees development and implementation of our overall compensati

View on Read The Filing